Tavneos® (avacopan) recommended by England's NICE for the treatment of AAV (GPA/MPA)Business Wire • 08/18/22
CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)PRNewsWire • 08/17/22
CSL Limited (CSLLY) CEO Paul Perreault on Q4 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/17/22
CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection TechnologyPRNewsWire • 08/04/22
Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. SeasonPRNewsWire • 07/11/22
CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and OlderPRNewsWire • 06/22/22
Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza VaccinesPRNewsWire • 06/06/22
Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic ReadyPRNewsWire • 06/02/22
CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding DisordersPRNewsWire • 04/28/22
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percentBusiness Wire • 03/23/22
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successfulBusiness Wire • 03/08/22
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percentBusiness Wire • 03/03/22
Forbes Magazine Ranks Global Biotech Leader CSL Among America's Best Employers for 2022PRNewsWire • 03/02/22
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and ResponsePRNewsWire • 02/25/22
CSL Plasma Makes $125,000 Donation to American Red Cross for Disaster Relief in U.S. CommunitiesPRNewsWire • 02/22/22
CSL Limited (CSLLY) CEO Paul Perreault on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/16/22
Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine TechnologyPRNewsWire • 02/07/22